Leiden University Scholarly Publications

Persistent URL of this record https://hdl.handle.net/1887/96560

In Collections

This item can be found in the following collections:

Jedema, I.; Balen, P. van; Halkes, C.J.M.; Egmond, E.H.M. van; Liempt, E.A.G. van; Veld, S.A.J.; ... ; Falkenburg, J.H.F. (2018)

Phase I/II clinical trial demonstrates feasibility, safety and effectivity of CMV-pp65-specific donor T-cells for the treatment of refractory CMV reactivation after allogeneic stem cell transplantation

Article / Letter to editor
All authors
Jedema, I.; Balen, P. van; Halkes, C.J.M.; Egmond, E.H.M. van; Liempt, E.A.G. van; Veld, S.A.J.; Hoogstraten, C.; Meij, P.; Kersting, S.; Zwaginga, J.J.; Rauser, G.; Assenmacher, M.; Falkenburg, J.H.F.
Date
2018-09-30
Journal
Bone Marrow Transplantation
Volume
53
Pages
45 - 45